RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06276283, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed and locally advanced or metastatic non-squamous NSCLC.

    Inclusion criterion 3

  3. Post-menopausal defined as age more than 60 and amenorrheic for at least 12 months after all exogenous hormonal treatments.

    Inclusion criterion 12

    Treatment with poziotinib, mobocertinib (TAK788), CLN-081, BDTX-189, aumolertinib, AP-L1898, and other EGFR Exon20ins inhibitors prior to the first dose of study drug (only applicable to Part B).

    Exclusion criterion 2

    Prior treatment with 1st to 3rd generation EGFR-TKIs (e.g., gefitinib, erlotinib, icotinib, osimertinib, afatinib, dacomitinib, and ametinib) and have had an objective response (i.e., PR and CR) (only applicable to Part B).

    Exclusion criterion 3

    Any unresolved toxicities from prior systemic therapy (e.g., adjuvant chemotherapy and radiotherapy) > CTCAE grade 1 at the time of starting study drug except for alopecia and grade 2 neuropathy related to previous platinum-based therapy.

    Exclusion criterion 14

  4. Written documentation of EGFR mutations from an accredited local laboratory: Part A is not limited to a specific EGFR mutation, and Part B only includes patients with EGFR Exon20ins.

    Inclusion criterion 4

    Treatment with EGFR, HER2, or VEGFR antibody within 4 weeks of the first dose of study drug.

    Exclusion criterion 5

    Concurrent EGFR mutations with approved EGFR-TKIs (e.g., Exon19del, L858R, T790M, G718X, S768I and L861Q; only applicable to Part B).

    Exclusion criterion 12

    Absolute neutrophil count < 1.5 × 109/L

    Exclusion criterion 27

    Platelet count < 100 ×109/L

    Exclusion criterion 28

    Hemoglobin < 9 g/dL

    Exclusion criterion 29

    Total bilirubin >1.5 × ULN if no liver metastases or >3 × the upper limit of normal (ULN) in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases

    Exclusion criterion 30

    Alanine aminotransferase (ALT) and aspartate aminotransferase (AST >2.5 × ULN if no demonstrable liver metastases or >5 × ULN in the presence of liver metastases.

    Exclusion criterion 31

    Creatinine ≥1.5 × ULN or creatinine clearance <50 mL/min (measured or calculated by Cockcroft and Gault equation)

    Exclusion criterion 32

    The international normalized ratio > 1.5 × ULN and activated partial thromboplastin time (APTT) > 1.5 × ULN

    Exclusion criterion 33

    Serum lipase) > 1.5 × ULN and serum amylase > 1.5 × ULN

    Exclusion criterion 34

  5. Patients with stable brain metastasis provided no evidence of progression for at least 2 weeks, as ascertained by brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the screening period, no neurological symptoms, and no requirement of Steroids.

    Inclusion criterion 6

    Measurable lesions, according to RECIST 1.1: at least one lesion, not previous irradiated, with the longest diameter ≥ 10 mm at baseline (lymph nodes must have a short axis of ≥ 15 mm), that can be accurately measured at baseline and thereafter with MRI or CT scan.

    Inclusion criterion 9

  6. History of malignancy within 2 years of the first dose of study drug (excluding adequately treated Basal cell carcinoma or in situ cervical cancer with a tumor-free period of more than 2 years and a life expectancy of more than 2 years. The inclusion of such patients should be discussed with the study physician from Dizal Pharma).

    Exclusion criterion 13

    Any evidence of active infection, including but not limited to hepatitis B, hepatitis C, human immunodeficiency virus (HIV), and COVID-19. The diagnosis of COVID-19 follows the local practice.

    Exclusion criterion 17

  7. Male patients with a female partner or fertility desire should be willing to use barrier contraception (e.g., condoms) until 6 months after the last dose. Male patients should not donate sperms until 6 months after the last dose. Male patients with fertility desire are suggested to freeze their sperm before entering the study.

    Inclusion criterion 10

    Pregnant women or women who are breastfeeding.

    Exclusion criterion 36

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06276283, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

Patients must meet all the following criteria for inclusion in the study:

  • Sufficient understanding of nature of the trial and provision of informed consent with hand-written signatures and the date of signature prior to any study-specific procedures, sampling, and analyses.
  • Age ≥ 18 years.
  • Histologically or cytologically confirmed and locally advanced or metastatic non-squamous NSCLC.
  • Written documentation of EGFR mutations from an accredited local laboratory: Part A is not limited to a specific EGFR mutation, and Part B only includes patients with EGFR Exon20ins.
  • ECOG score ≤ 1 without clinically significant disease deterioration within 2 weeks prior to the informed consent process and a life expectancy ≥ 12 weeks.
  • Patients with stable brain metastasis provided no evidence of progression for at least 2 weeks, as ascertained by brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the screening period, no neurological symptoms, and no requirement of Steroids.
  • Part A includes patients who have progressed after or cannot tolerate the standard of care
  • Part B includes patients with NSCLC who have progressed after or cannot tolerate standard of care. Treatment naïve patients will be enrolled after an adequate evaluation of the safety data by the Safety Review Committee (Note: Patients who have received (neo)adjuvant therapy are allowed to participate in the study, if the (neo)adjuvant therapy is administrated at least 6 months prior to the diagnosis of locally advanced or metastatic NSCLC) .
  • Measurable lesions, according to RECIST 1.1: at least one lesion, not previous irradiated, with the longest diameter ≥ 10 mm at baseline (lymph nodes must have a short axis of ≥ 15 mm), that can be accurately measured at baseline and thereafter with MRI or CT scan.
  • Male patients with a female partner or fertility desire should be willing to use barrier contraception (e.g., condoms) until 6 months after the last dose. Male patients should not donate sperms until 6 months after the last dose. Male patients with fertility desire are suggested to freeze their sperm before entering the study.
  • Female patients should be willing to use adequate contraceptive measures, should not be breastfeeding, and must have a negative pregnancy test (i.e., urine and blood pregnancy human chorionic gonadotropin testing); or female patients meet the following criteria:
  • Post-menopausal defined as age more than 60 and amenorrheic for at least 12 months after all exogenous hormonal treatments.
  • Women under 60 years old would be considered post-menopausal if they have been amenorrheic for at least 12 months with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range.
  • Documentation of irreversible surgical sterilization (e.g., hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation).

Exclusion Criteria:

Patients must not enter the study if any of the following exclusion criteria are met:

  • Treatment with any of the following:
  • Treatment with poziotinib, mobocertinib (TAK788), CLN-081, BDTX-189, aumolertinib, AP-L1898, and other EGFR Exon20ins inhibitors prior to the first dose of study drug (only applicable to Part B).
  • Prior treatment with 1st to 3rd generation EGFR-TKIs (e.g., gefitinib, erlotinib, icotinib, osimertinib, afatinib, dacomitinib, and ametinib) and have had an objective response (i.e., PR and CR) (only applicable to Part B).
  • Prior systemic treatment for locally advanced or metastatic NSCLC (only applicable to treatment naïve patients in Part B)
  • Treatment with EGFR, HER2, or VEGFR antibody within 4 weeks of the first dose of study drug.
  • Chemotherapy or other anti-tumor therapies within 2 weeks of the first dose of study drug.
  • Radiotherapy within 14 days of the first dose of study drug or unresolved radiotherapy-related toxicities. Patients could receive palliative radiotherapy for tumor lesions outside of brain and chest, stereotactic radiosurgery, and stereotactic body radiotherapy.
  • Current treatment within 1-2 weeks of the first dose of study drug with medications or herbal supplements known to be potent inhibitors (1 week) or inducers (2 weeks) of cytochrome P450 (CYP) 3A4.
  • Major surgery, excluding biopsy and diagnostic surgery, within 4 weeks of the dose of study drug, or expected major surgeries during the study period.
  • Treatment with an investigational drug within 5 half-lives of the compound. Patient
  • Spinal cord compression or leptomeningeal metastasis.
  • Concurrent EGFR mutations with approved EGFR-TKIs (e.g., Exon19del, L858R, T790M, G718X, S768I and L861Q; only applicable to Part B).
  • History of malignancy within 2 years of the first dose of study drug (excluding adequately treated Basal cell carcinoma or in situ cervical cancer with a tumor-free period of more than 2 years and a life expectancy of more than 2 years. The inclusion of such patients should be discussed with the study physician from Dizal Pharma).
  • Any unresolved toxicities from prior systemic therapy (e.g., adjuvant chemotherapy and radiotherapy) > CTCAE grade 1 at the time of starting study drug except for alopecia and grade 2 neuropathy related to previous platinum-based therapy.
  • History of stroke and intracranial hemorrhage within 6 months of the first dose of study drug.
  • Any evidence of severe or uncontrolled systematic disease based on the investigator's opinion, including uncontrolled hypertension and active bleeding diatheses (e.g., hemophilia and von Willebrand disease).
  • Any evidence of active infection, including but not limited to hepatitis B, hepatitis C, human immunodeficiency virus (HIV), and COVID-19. The diagnosis of COVID-19 follows the local practice.

Test Include if Exclude if HIV antibody (-) (+) HCV antibody (-) (+) HBV antibody HbsAg (-) and HbcAb (-) HbsAg (+) and HBV DNA ≥ 1000 IU/mL HbsAg (-), HbcAb (+) and HBV DNA < 1000 IU/mL HbsAg (-), HbcAb (+), and HBV DNA ≥ 1000 IU/mL (-), Negative; (+), Positive.

  • Any of the following cardiac events or abnormalities:
  • Mean resting corrected QT interval (QTcF) > 470 msec.
  • Any clinically significant abnormalities in rhythm, conduction, or morphology detected by resting ECG, e.g., complete left bundle branch block, third-degree heart block, second-degree heart block, and PR interval > 250 msec.
  • Any factors that can lead to QTcF prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, family history of unexplained sudden death under 40 years of age, or any comorbidities known to prolong the QT interval.
  • Any evidence of atrial fibrillation (except for drug-related atrial fibrillation that has been resolved after drug discontinuation).
  • Any evidence of myocadiac infraction, congestive heart failure (New York Heart Association Class II or above), and uncontrolled arrhythmia with medication within 6 months of the first dose of study drug.
  • History of interstitial lung disease (ILD), drug-induced ILD, and immune-related pneumonitis due to cancer immunotherapy.
  • Refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing the study drug, or previous bowel resection that would preclude adequate absorption of DZD9008.
  • Inadequate bone marrow reserve or organ function:
  • Absolute neutrophil count < 1.5 × 109/L
  • Platelet count < 100 ×109/L
  • Hemoglobin < 9 g/dL
  • Total bilirubin >1.5 × ULN if no liver metastases or >3 × the upper limit of normal (ULN) in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST >2.5 × ULN if no demonstrable liver metastases or >5 × ULN in the presence of liver metastases.
  • Creatinine ≥1.5 × ULN or creatinine clearance <50 mL/min (measured or calculated by Cockcroft and Gault equation)
  • The international normalized ratio > 1.5 × ULN and activated partial thromboplastin time (APTT) > 1.5 × ULN
  • Serum lipase) > 1.5 × ULN and serum amylase > 1.5 × ULN
  • Live virus vaccines administrated within 2 weeks of the first dose of study drug.
  • Pregnant women or women who are breastfeeding.
  • Concurrent contraindications to bevacizumab, including but not limited to:
  • Deep vein thrombosis ≥ CTCAE grade 3
  • Uncontrolled hypertension (systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg)
  • Intracerebral hemorrhage, including hemorrhage caused by metastatic brain tumors.
  • History of severe proteinuria (urine dipstick protein 2+ or 24-hour urine protein > 2g)
  • History of hypertensive crisis and hypertensive encephalopathy
  • History of central nervous system diseases that are not related to the tumor (e.g., convulsions)
  • History of vascular events within 6 months of the first dose of study drug (e.g., aneurysm requiring treatment)
  • History of hemoptysis within 3 months of the first dose of study drug (two spoonfuls of blood each time)
  • History of bleeding disorders or coagulation disorders without treatment of anticoagulants.
  • Tumor invasion of major vessels
  • History of gastrointestinal perforation or fistula within 6 months of the first dose of study drug
  • Severe allergic reaction to DZD9008, bevacizumab, or their excipients.
  • Subjects who are involved in the design, planning, or conduct of the study (applicable to employees of Dizal Pharm and staff at investigational sites).
  • Poor compliance or inability to participate in clinical studies according to the investigator's assessment.

Quoted from ClinicalTrials.gov, NCT06276283, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06276283, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06276283